<DOC>
	<DOCNO>NCT01369433</DOCNO>
	<brief_summary>Open-label , multi-center , multi-national rollover study allow continued access tivozanib subject participate tivozanib ( monotherapy combination ) protocols . Eligible subject continue receive tivozanib dose schedule per original ( parent ) protocol . The length time subject must parent protocol roll protocol dictate ( original ) parent protocol . Subjects see investigator every 4 week ( Â± 5 day ) . Adverse event blood pressure record . At begin Cycle 1 begin every odd-numbered cycle ( Cycle 3 , Cycle 5 , etc ) , clinical laboratory value record . CT scan assess disease perform end even-numbered cycle ( Cycle 2 , Cycle 4 , etc ) .</brief_summary>
	<brief_title>A Rollover Protocol Allow Continued Access Tivozanib ( AV 951 ) Subjects Enrolled Other Tivozanib Protocols</brief_title>
	<detailed_description>This open-label multi-center , multi-national rollover protocol allow continued access tivozanib subject participate tivozanib ( monotherapy combination ) protocols , tolerate study drug , display clinical benefit . Enrollment protocol remain open subject participate current future protocol tivozanib . The end study last treatment visit last subject last site . Enrollment protocol continue tivozanib becomes commercially available country subject treat . If subject experience clinical benefit tivozanib study discontinue , sponsor make every effort assist subject obtain commercially available tivozanib . This rollover protocol open eligible subject current future protocol tivozanib . The number subject enroll dependent upon number subject enrol tivozanib protocol tolerate drug , display clinical benefit , willing participate .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . The subject must receive tivozanib enrol another protocol , must tolerate study drug must currently display clinical benefit . The length time subject must parent protocol roll protocol dictate parent protocol . 2 . If female childbearing potential , documentation negative pregnancy test prior enrollment . 3 . Ability give write informed consent . 1 . &gt; 4 week since discontinuation tivozanib treatment previous protocol 2 . If female , pregnant lactate 3 . Sexually active male premenopausal female subject ( partner ) unless agree use adequate contraceptive measure , study 30 day last dose study drug . All fertile male female subject ( partner ) must agree use highly effective method contraception . Highly effective birth control include ( ) IUD plus one barrier method ; ( b ) 2 barrier method . Effective barrier method male female condom , diaphragm , spermicide ( creams gel contain chemical kill sperm ) . ( Note : Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , consider effective study . ) 4 . Uncontrolled hypertension : systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mmHg 2 antihypertensive medication , document 2 consecutive measurement take least 24 hour apart . 5 . Newly identify CNS malignancy document progression CNS metastases ; subject allow CNS metastasis adequately treat radiotherapy surgery . For subject receive steroid therapy please refer Section 6.3 allow steroid maintenance therapy . 6 . Unhealed wound ( include active peptic ulcer ) 7 . Serious/active infection infection require parenteral antibiotic 8 . Lifethreatening illness organ system dysfunction compromise safety evaluation 9 . Psychiatric disorder , alter mental status precluding inform consent necessary test 10 . Inability comply protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>tivozanib</keyword>
</DOC>